Intellectual Property Magazine
The fine line
Chris Worrall and Sandra Mapara discuss the pay-for-delay case against drug firms Aspen, Amilco and Tiofarma that resulted in fines totalling £2.3m
Chris Worrall and Sandra Mapara - Burges Salmon
The UK’s Competition and Markets Authority (CMA) has imposed fines totalling almost £2.3m on three pharmaceutical companies
for infringing competition law in relation to the supply of fludrocortisone acetate tablets in the UK.
1 Fludrocortisone is a prescription-only medicine mainly used to treat primary or secondary adrenal insufficiency (Addison’s
disease). The CMA considered that drug firms Amilco and Tiofarma agreed to stay out of the fludrocortisone market in exchange
for payment and other terms (pay for delay) so that Aspen could maintain its position as the sole supplier in the UK.